GlassScriptPhysician profile
Spencer A Lau
NPI 1427194083
$2,415.02
in general payments reported to CMS, 2019-2025
19 companies · $529 in 2025
The $529 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $47.19 · 2021: $460 · 2022: $444 · 2023: $217 · 2024: $242 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.26 | 2021-2025 | |
| Eisai INC. | $312.16 | 2021-2022 | |
| Medtronic USA, INC. | $225.69 | 2019 | |
| Mml US, INC. | $176.00 | 2025 | Reactiv8 |
| Lilly USA, LLC | $173.54 | 2022-2024 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $151.95 | 2019-2020 | |
| Pfizer INC. | $135.28 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $124.83 | 2024 | Fasenra |
| Vertex Pharmaceuticals Incorporated | $121.85 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.45 | 2023 | |
| Boston Scientific Corporation | $105.67 | 2025 | General - Pain Management |
| Kowa Pharmaceuticals America, INC. | $41.52 | 2022-2023 | Livalo, Seglentis |
| Novo Nordisk INC | $34.87 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $33.41 | 2022-2023 | Quviviq |
| Amgen INC. | $28.98 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.23 | 2023 | Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $23.31 | 2022 | |
| Horizon Therapeutics Plc | $18.01 | 2021 | |
| Abbott Laboratories | $16.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.